For Research Use Only. All content is intended for scientific reference only and does not constitute medical advice.

Most peptides generating research interest in 2026 are products of American or European pharmaceutical pipelines. Semax and Selank are not. Both were developed at the Institute of Molecular Genetics in Moscow, both have been registered medicines in Russia and Ukraine for years, and both are now attracting serious attention from Western neuroscience researchers who are only beginning to investigate what Russian scientists have been publishing for three decades.

Semax is a synthetic heptapeptide derived from the N-terminal fragment of ACTH, the pituitary hormone involved in stress response regulation. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro. What makes it unusual is that despite its ACTH origin, it does not carry ACTH's hormonal activity. Instead it acts on melanocortin receptors in the CNS and, critically, on the BDNF/TrkB signalling system.

BDNF, brain-derived neurotrophic factor, is one of the most important proteins in neurological research. It regulates neuronal survival, differentiation, synaptic plasticity, and neuroprotection. Semax has been shown to upregulate BDNF gene expression in the hippocampus and frontal cortex in rodent models, with measurable changes appearing within 20 minutes of administration and persisting for up to 24 hours. This BDNF pathway is one of the best-characterised mechanisms in modern neuropeptide research and is the primary reason Semax is attracting Western laboratory interest.

The 2025 research on Semax added a second, distinct mechanism that had not been previously identified. A study published in Bioinorganic Chemistry and Applications found that Semax is a copper chelator capable of extracting Cu(II) from amyloid-beta/copper complexes and reducing the reactive oxygen species they generate. This is a mechanistically separate neuroprotective pathway from BDNF activity and positions Semax as a compound of interest in oxidative stress and neurodegeneration research independently of its neurotrophic effects. A separate 2025 study in transgenic Alzheimer's disease mouse models found measurable improvements in spatial memory and cognitive function markers across multiple behavioural tests following Semax administration.

Selank is a different compound with a different origin. It is a synthetic heptapeptide analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide found in immunoglobulin G. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Where Semax acts primarily through neurotrophic signalling, Selank acts primarily through the GABAergic system, the brain's main inhibitory signalling network.

Research has shown Selank modulates the mRNA expression of multiple genes involved in GABAergic neurotransmission in the frontal cortex, including changes appearing within one hour of administration. It also inhibits enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, which may contribute to its broader neurological activity. Unusually for a CNS peptide, Selank also demonstrates immunomodulatory properties through its tuftsin origin, making it relevant to research examining the interaction between immune signalling and CNS function.

The two compounds are often studied together because their mechanisms are complementary rather than overlapping. Semax drives neurotrophic and neuroprotective signalling. Selank modulates inhibitory neurotransmission and immune-CNS crosstalk. Neither compound has completed large-scale human clinical trials outside Russia. In Russian clinical settings, Selank has been compared directly to benzodiazepines in generalised anxiety disorder models, with findings suggesting comparable anxiolytic activity and a notably cleaner tolerability profile. That data has not been independently replicated in Western trial settings, and it should be treated accordingly.

What is changing in 2026 is the regulatory context. Both Semax and Selank were among the compounds referred for PCAC review by the FDA in April 2026, signalling formal regulatory attention to their research status for the first time in the United States. That attention tends to accelerate published Western research. The body of data is already moving.

References

Sudarkina OY et al. Int J Mol Sci. 2021. PMC8226508
Dolotov OV et al. J Neurochem. 2006. PMID: 19662538
Tomasello MF et al. Bioinorg Chem Appl. 2025. PMC12151629
Inozemtseva LS et al. GABAergic gene expression and Selank. PMC4757669
Semax vs Selank research comparison. Palmetto Peptides. April 2026
Semax and Selank cognitive peptides. Meto Blog. June 2026

‍